ST交昂(600530) - 2023 Q3 - 季度财报

Financial Performance - Q3 2023 revenue decreased by 33.93% year-on-year to CNY 67,554,601.59, and year-to-date revenue decreased by 5.13% to CNY 250,616,807.08[3] - Net profit attributable to shareholders was CNY -9,088,221.67, a decline of 141.80% year-on-year, with year-to-date net profit at CNY -29,762,356.02, down 209.85%[3] - Basic earnings per share for Q3 2023 was CNY -0.01, a decrease of 139.09% compared to the same period last year, and year-to-date earnings per share was CNY -0.04, down 228.02%[4] - Net profit for Q3 2023 was a loss of CNY 25,502,918.99, compared to a profit of CNY 31,126,773.26 in Q3 2022, indicating a significant decline[16] - The total comprehensive income attributable to shareholders for Q3 2023 was a loss of CNY 29,762,356.02, compared to a gain of CNY 16,565,035.58 in Q3 2022[16] - Basic and diluted earnings per share for Q3 2023 were both CNY -0.04, down from CNY 0.03 in Q3 2022, indicating a negative shift in profitability[17] Assets and Liabilities - Total assets at the end of the reporting period were CNY 796,553,998.06, a decrease of 9.98% from the end of the previous year[4] - Shareholders' equity attributable to the parent company decreased by 9.04% to CNY 299,285,875.44 compared to the end of the previous year[4] - The total liabilities decreased from RMB 324,786,805.08 to RMB 270,787,333.84, a decrease of approximately 16.6%[12] - The company's total liabilities decreased to CNY 451,766,681.77 in Q3 2023 from CNY 514,535,641.64 in Q3 2022, reflecting a reduction of approximately 12.2%[14] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 41,347,820.75, down 30.01%[3] - Cash inflow from operating activities for the first three quarters of 2023 was CNY 298,704,800.16, slightly up from CNY 296,012,563.03 in the same period of 2022[18] - Net cash flow from operating activities decreased to CNY 41,347,820.75 in 2023 from CNY 59,080,805.46 in 2022, representing a decline of approximately 30.1%[18] - Cash inflow from financing activities totaled CNY 51,000,000.00 in Q3 2023, with cash outflow amounting to CNY 102,768,492.55, leading to a net cash flow of CNY -51,768,492.55[18] Receivables and Inventory - The company reported a 38.77% decrease in accounts receivable year-to-date, attributed to the recovery of management fees and other receivables[6] - Accounts receivable decreased from RMB 86,832,169.63 to RMB 53,164,443.91, a reduction of about 38.8%[12] - The company reported a decrease in inventory from RMB 50,085,779.78 to RMB 48,727,010.90, a decline of about 2.7%[12] Expenses and Costs - Financial expenses for Q3 2023 increased by 749.54%, primarily due to interest on bank loans and lease liabilities[6] - Total operating costs for the first three quarters of 2023 were CNY 231,815,773.39, slightly increased from CNY 231,640,163.95 in 2022[15] - Research and development expenses for the first three quarters of 2023 were CNY 7,414,003.31, down from CNY 11,716,242.18 in the same period of 2022, representing a decrease of approximately 36.5%[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 24,795[8] - The top 10 shareholders hold a total of 396,000,000 shares, representing 50.56% of the total shares[9] Government Support - The company received government subsidies amounting to CNY 652,425.49 during the reporting period, which are closely related to its normal operations[5] Other Financial Metrics - The company has a long-term investment of RMB 39,887,507.36, slightly down from RMB 40,946,153.54[12] - The company's deferred income increased to CNY 16,088,960.00 in Q3 2023 from CNY 11,628,519.80 in Q3 2022, reflecting a growth of approximately 38.2%[14] - The company experienced a 100% decrease in long-term borrowings year-to-date, as it repaid loans from Shanghai Bank[6] - The company's financial liabilities due within one year decreased to CNY 53,138,650.46 in Q3 2023 from CNY 65,801,378.29 in Q3 2022, a reduction of approximately 19.2%[14] Future Outlook - The company anticipates a significant reduction in revenue from the medical and nursing sector due to the termination of management consulting agreements by several non-profit organizations[10] - The company has not provided any new product or technology development updates in the current report[10]